InvusAdage Capital ManagementVenrock Healthcare Capital PartnersRTW InvestmentsOrbimedFranklin TempletonEli Lilly And CompanyHBM Healthcare InvestmentsJanus Henderson InvestorsBalyasny Asset Management
Description
Lycia Therapeutics, based in South San Francisco, California, raised $75m in Series D funding. The round was co-led by Janus Henderson Investors and Balyasny Asset Management, with participation from various investors. The funds will be used to advance its lead cataLYTAC pipeline programs for food allergy and Graves’ disease. The company's leadership has recently strengthened its corporate governance.
Who to call at Lycia Therapeutics, Inc., and when
A new round usually means Lycia Therapeutics, Inc. is about to hire and buy. The teams that reach out first get the meeting.
An alert the day Lycia Therapeutics, Inc. raises, hires an executive or expands, scored against what you sell
The decision-makers there, with verified emails
Who you already know at Lycia Therapeutics, Inc., from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Lycia Therapeutics, Inc.. With Fundz connected, it knows.
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
Company Information
Company
Lycia Therapeutics, Inc.
Location
400 East Jamie Court, Suite 200
South San Francisco, California, United States
About
Lycia is a Series B biotech company building upon the novel platform developed by academic founder Professor Carolyn Bertozzi at Stanford University to develop LYTAC (lysosomal targeting chimera) protein degraders that harness the cell’s lysosomal trafficking and degradation pathway to target both soluble and membrane-bound extracellular proteins. Applications of the LYTAC platform include: targeting challenging membrane proteins, clearing pathogenic immune complexes in circulation and depleting antibodies to specific antigens of interest. The platform can potentially deliver next-generation therapeutics to address a range of difficult-to-treat diseases, including cancer and autoimmune diseases.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment Lycia Therapeutics, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.
South San FranciscoBiotechnology